ClinicalTrials.gov
ClinicalTrials.gov Menu

A Clinical Trial Evaluating the Effect of ASLAN001 in Patients With Recurrent/Metastatic Gastric Cancer Whose Tumors Are Either HER-2 Amplified or Co-expressing HER-1 and HER-2

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01614522
Recruitment Status : Completed
First Posted : June 8, 2012
Last Update Posted : January 14, 2015
Sponsor:
Information provided by (Responsible Party):
Aslan Pharmaceuticals

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : March 2013
  Actual Study Completion Date : March 2013